Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 226

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 226
---
 force or effect and neither FSF nor we shall have any further liability or obligations thereunder. In consideration of Endeavor assuming our payment obligation in respect of
the FSF Deposit, Endeavor will not be responsible for making any payment to us for (i) the product already delivered as of the date of such agreement in an amount of approximately $13.2 million and (ii) the Additional Product. In
November 2024, we delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit.

Tranche B Notes

On October 7, 2024, we entered into a securities purchase agreement (the “Tranche B Securities Purchase Agreement
with the Tranche B Noteholders to refinance a portion of the Oramed Note and pay off certain other indebtedness. Pursuant to the Tranche B Securities Purchase Agreement, we agreed to issue and sell, in a registered offering directly to the Tranche B
Noteholders: (i) the Tranche B Notes, which notes will mature on the two-year anniversary of the issuance date and are convertible into shares of our Common Stock at a conversion price equal to $38.15 per
share (which was automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes) and (ii) the October 2024 Noteholder Warrants to purchase up to
214,284 shares of our Common Stock directly to the Tranche B Noteholders.

In exchange for the issuance of the Tranche B Notes to the
Tranche B Investors, the Company received an aggregate amount of $22,500,000 in cash, excluding fees and expenses payable by us. We received from Oramed

151

in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note of $22,500,000.

The October 2024 Noteholder Warrants are immediately exercisable for cash at an exercise price equal to $38.15 per share of Common Stock
(which was automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO in accordance with the terms of such notes) and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to
the Tranche B Investors are initially exercisable for 107,142 shares of Common Stock in the aggregate. The